Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Zhou Z, Zhu Y, Chu M. Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Front Immunol 2022;13:898192. [PMID: 35669787 PMCID: PMC9165056 DOI: 10.3389/fimmu.2022.898192] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 04/19/2022] [Indexed: 12/28/2022] Open

For:	Zhou Z, Zhu Y, Chu M. Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Front Immunol 2022;13:898192. [PMID: 35669787 PMCID: PMC9165056 DOI: 10.3389/fimmu.2022.898192] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 04/19/2022] [Indexed: 12/28/2022] Open

Number

Cited by Other Article(s)

Luo S, Yin L, Liu X, Wang X. Advances in Virus Biorecognition and Detection Techniques for the Surveillance and Prevention of Infectious Diseases. BIOSENSORS 2025;15:198. [PMID: 40136995 PMCID: PMC11940537 DOI: 10.3390/bios15030198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/23/2025] [Revised: 03/14/2025] [Accepted: 03/18/2025] [Indexed: 03/27/2025]

Chen Y, Chen C. The effect of inflammatory proteins on COVID-19 is mediated by blood metabolites: A Mendelian randomization study. Medicine (Baltimore) 2025;104:e41852. [PMID: 40101060 PMCID: PMC11922457 DOI: 10.1097/md.0000000000041852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Accepted: 02/24/2025] [Indexed: 03/20/2025] Open

Silva Ramírez B, Peñuelas Urquides K, Escobedo Guajardo BL, Mata Tijerina VL, Cruz Luna JE, Corrales Pérez R, Gómez García S, González Escalante LA, Camacho Moll ME. Assessment of COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Infection, Hospitalization and Death in Mexican Patients with Metabolic Syndrome from Northeast Mexico: A Multicenter Study. Vaccines (Basel) 2025;13:244. [PMID: 40266114 PMCID: PMC11945729 DOI: 10.3390/vaccines13030244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2024] [Revised: 12/27/2024] [Accepted: 01/01/2025] [Indexed: 04/24/2025] Open

Wen Z, Wang T, Luo S, Liu Y. CT scan-derived pectoralis muscle parameters are closely associated with COVID-19 outcomes: A systematic review and meta-analysis. PLoS One 2025;20:e0316893. [PMID: 39874384 PMCID: PMC11774355 DOI: 10.1371/journal.pone.0316893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2024] [Accepted: 12/17/2024] [Indexed: 01/30/2025] Open

Cavalli M, Campoli G, Anselmo A, Brandi R, Fortunato A, Di Spirito M, Monte A, Lipari M, Bortone M, Fain VV, D'Amelio R, Lista F, Fillo S. Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era. Sci Rep 2025;15:3372. [PMID: 39870695 PMCID: PMC11772649 DOI: 10.1038/s41598-024-84952-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Accepted: 12/30/2024] [Indexed: 01/29/2025] Open

Justiz-Vaillant A, Roopnarine K, Solomon S, Phillips A, Sandy S, Subero A, Seepersad S, Span N, Ramnath P, Ramnarine A, Ramdath B, Rampaul C, Ramdial R, Phagoo D, Ramdhanie T, Moonilal V, Poliah EM, Poonwassie S, Punilal K, Panchoo S, Parris J, Oudit S, Muir T, Nicholas-Joseph J, Pandit BR, Pakeerah S, Sookoo V, Richards P, John T, Gopaul D, Soodeen S, Arozarena-Barbosa O, Williams A, Unakal C, Fundora RA, Thompson R, Akpaka PE. COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis. Microorganisms 2025;13:135. [PMID: 39858903 PMCID: PMC11767614 DOI: 10.3390/microorganisms13010135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2024] [Revised: 12/03/2024] [Accepted: 01/07/2025] [Indexed: 01/27/2025] Open

Affiliation(s)

Angel Justiz-Vaillant Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Kimberly Roopnarine Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Shaundell Solomon Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Alyssa Phillips Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Solange Sandy Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Alyssa Subero Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Sarah Seepersad Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Nicholas Span Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Phalmanie Ramnath Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Akaasha Ramnarine Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Bimala Ramdath Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Chelsea Rampaul Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Renissa Ramdial Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Dana Phagoo Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Thalia Ramdhanie Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Vinaya Moonilal Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Emily-Marie Poliah Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Steffan Poonwassie Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Karishta Punilal Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Sarah Panchoo Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Justice Parris Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Steven Oudit Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Trudy Muir Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Johnson Nicholas-Joseph Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Bijey Raj Pandit Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Sanjeev Pakeerah Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Vesham Sookoo Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Patrice Richards Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Tishia John Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Darren Gopaul Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA;
Sachin Soodeen Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Odette Arozarena-Barbosa Eric Williams Medical Sciences Complex, North Central Regional Health Authority, Champs Fleurs 330912, Trinidad and Tobago (R.A.F.)
Arlene Williams Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Chandrashehkar Unakal Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Rodolfo Arozarena Fundora Eric Williams Medical Sciences Complex, North Central Regional Health Authority, Champs Fleurs 330912, Trinidad and Tobago (R.A.F.) Department of Clinical and Surgical Sciences, Faculty of Medical Sciences, University of the West Indies, St. Augustine 330912, Trinidad and Tobago
Reinand Thompson Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Patrick Eberechi Akpaka Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)

Collapse

Cao Y, Yao T, Li R, Tan L, Zhang Z, Qi J, Zhang R, Wu Y, Chen Z, Yin C. Clinical characteristics and prediction model of re-positive nucleic acid tests among Omicron infections by machine learning: a real-world study of 35,488 cases. BMC Infect Dis 2024;24:1406. [PMID: 39695973 DOI: 10.1186/s12879-024-10297-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Accepted: 12/02/2024] [Indexed: 12/20/2024] Open

Abstract

BACKGROUND

During the Omicron BA.2 variant outbreak in Shanghai, China, from April to May 2022, PCR nucleic acid test re-positivity (TR) occurred frequently, yet the risk factors and predictive models for TR remain unclear. This study aims to identify the factors influencing Omicron TR and to develop machine learning models to predict TR risk. Accurately predicting re-positive patients is crucial for identifying high-risk individuals, optimizing resource allocation, and developing personalized treatment and management plans, thereby effectively controlling the spread of the epidemic, reducing community burden, and ensuring public health.

METHODS

A retrospective study was conducted among individuals infected with Omicron BA.2 variant from April 12 to May 25, 2022, in the largest Shanghai Fangcang shelter hospital. Five machine learning models were compared, including k-nearest-neighbors (KNN), logistic regression (logistic), bootstrap aggregation (bagging), error back-propagation (BP) neural network, and support vector machines (SVM), to select the best prediction model for the TR risk factors.

RESULTS

A total of 35,488 cases were included in this real-world study. The TR and control groups comprised of 6,171 and 29,317 cases respectively, with a re-positive rate of 17.39%. Higher occurrence of TR was observed in young age, males, those with obvious symptoms, underlying diseases, and a low Ct value. The KNN model proved to be the best in predicting the prognosis in the overall evaluation (accuracy = 0.8198, recall = 0.8026, and AUC = 0.8110 in the test set).

INTERPRETATION

Higher TR risk was found in infected cases who were underage or with underlying diseases; vaccine brand and inoculation status were not significantly associated with TR. KNN was the most effective machine learning model to predict TR occurrence in isolation.

Collapse

Affiliation(s)

Ying Cao Department of Critical Care Medicine, The first affiliated hospital(Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, 400038, China
Tianhua Yao Department of Health Statistics, Faculty of Military Preventive Medicine, Army Medical University (Third Military Medical University), No. 30, Gaotan Yanzheng Street, Shapingba District, Chongqing, 400038, China
Ronghao Li School of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing, 400038, China
Liang Tan Department of Critical Care Medicine, The first affiliated hospital(Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, 400038, China
Zhixiong Zhang School of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing, 400038, China
Junsheng Qi Department of Critical Care Medicine, The first affiliated hospital(Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, 400038, China
Rui Zhang Department of Critical Care Medicine, The first affiliated hospital(Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, 400038, China
Yazhou Wu Department of Health Statistics, Faculty of Military Preventive Medicine, Army Medical University (Third Military Medical University), No. 30, Gaotan Yanzheng Street, Shapingba District, Chongqing, 400038, China.
Zhiqiang Chen Department of Pediatrics, The first affiliated hospital(Southwest Hospital), Army Medical University (Third Military Medical University), No. 30, Gaotan Yanzheng Street, Shapingba District, Chongqing, 400038, China.
Changlin Yin Department of Critical Care Medicine, The first affiliated hospital(Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, 400038, China.

Collapse

Brandi R, Paganelli A, D’Amelio R, Giuliani P, Lista F, Salemi S, Paganelli R. mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases. Vaccines (Basel) 2024;12:1418. [PMID: 39772079 PMCID: PMC11680146 DOI: 10.3390/vaccines12121418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2024] [Revised: 12/07/2024] [Accepted: 12/13/2024] [Indexed: 01/03/2025] Open

Abstract

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy to adapt should the antigen vary, and able to induce humoral and cellular immunity.

METHODS

To date, only two COVID-19 mRNA and one RSV vaccines have been approved. However, several mRNA vaccines are currently under development for the prevention of human viral (influenza, human immunodeficiency virus [HIV], Epstein-Barr virus, cytomegalovirus, Zika, respiratory syncytial virus, metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster virus, and herpes simplex virus 1 and 2), bacterial (tuberculosis), and parasitic (malaria) diseases.

RESULTS

RNA viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV)-2, HIV, and influenza, are characterized by high variability, thus creating the need to rapidly adapt the vaccines to the circulating viral strain, a task that mRNA vaccines can easily accomplish; however, the speed of variability may be higher than the time needed for a vaccine to be adapted. mRNA vaccines, using lipid nanoparticles as the delivery system, may act as adjuvants, thus powerfully stimulating innate as well as adaptive immunity, both humoral, which is rapidly waning, and cell-mediated, which is highly persistent. Safety profiles were satisfactory, considering that only a slight increase in prognostically favorable anaphylactic reactions in young females and myopericarditis in young males has been observed.

CONCLUSIONS

The COVID-19 pandemic determined a shift in the use of RNA: after having been used in medicine as micro-RNAs and tumor vaccines, the new era of anti-infectious mRNA vaccines has begun, which is currently in great development, to either improve already available, but unsatisfactory, vaccines or develop protective vaccines against infectious agents for which no preventative tools have been realized yet.

Collapse

Kutumbetov L, Myrzakhmetova B, Tussipova A, Zhapparova G, Tlenchiyeva T, Bissenbayeva K, Zhapar K, Zhugunissov K, Nurabayev S, Kerimbayev A. Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results. Vaccines (Basel) 2024;12:1401. [PMID: 39772061 PMCID: PMC11728456 DOI: 10.3390/vaccines12121401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2024] [Revised: 12/03/2024] [Accepted: 12/09/2024] [Indexed: 01/16/2025] Open

Rancati S, Nicora G, Prosperi M, Bellazzi R, Salemi M, Marini S. Forecasting dominance of SARS-CoV-2 lineages by anomaly detection using deep AutoEncoders. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2023.10.24.563721. [PMID: 37961168 PMCID: PMC10634784 DOI: 10.1101/2023.10.24.563721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]

Hu Q, Zhang Y, Chen P, Zhang Y, Zhu G, Liu W, Wang C, Zheng S, Shen N, Wang H, Huang P, Ge G. Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 M^pro from the antiviral herb Ephedra. Chin J Nat Med 2024;22:797-807. [PMID: 39326974 DOI: 10.1016/s1875-5364(24)60577-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Indexed: 09/28/2024]

Affiliation(s)

Qing Hu Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China
Yiwen Zhang Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China
Pengcheng Chen Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China
Yani Zhang Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Guanghao Zhu Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Wei Liu Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China
Chaoran Wang Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
Shuilian Zheng Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China
Nonger Shen Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China
Haonan Wang Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Ping Huang Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China.
Guangbo Ge Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Collapse

Lu CK, Lung J, Shu LH, Liu HT, Wu YH, Lin YS, Yang YH, Wu YH, Wu CY. The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants. Int J Mol Sci 2024;25:9498. [PMID: 39273444 PMCID: PMC11394907 DOI: 10.3390/ijms25179498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2024] [Revised: 08/11/2024] [Accepted: 08/26/2024] [Indexed: 09/15/2024] Open

Shoemaker K, Soboleva K, Branche A, Shankaran S, Theodore DA, Bari M, Ezeh V, Green J, Kelly E, Lan D, Olsson U, Saminathan S, Shankar NK, Villegas B, Villafana T, Falsey AR, Sobieszczyk ME. Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study. Vaccines (Basel) 2024;12:883. [PMID: 39204009 PMCID: PMC11359581 DOI: 10.3390/vaccines12080883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2024] [Revised: 07/24/2024] [Accepted: 07/25/2024] [Indexed: 09/03/2024] Open

Affiliation(s)

Kathryn Shoemaker Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA; (K.S.); (D.L.)
Karina Soboleva Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA; (K.S.); (V.E.)
Angela Branche Division of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, NY 14627, USA;
Shivanjali Shankaran Division of Infectious Diseases, Rush University Medical Center, Chicago, IL 60612, USA;
Deborah A. Theodore Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian/Columbia University Irving Medical Center, New York, NY 10032, USA; (D.A.T.)
Muhammad Bari Formerly Patient Safety, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK;
Victor Ezeh Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA; (K.S.); (V.E.)
Justin Green Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
Elizabeth Kelly Formerly Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA;
Dongmei Lan Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA; (K.S.); (D.L.)
Urban Olsson Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden;
Senthilkumar Saminathan Patient Safety, Chief Medical Office, R&D, AstraZeneca, Bangalore 560045, India; (S.S.); (N.K.S.)
Nirmal Kumar Shankar Patient Safety, Chief Medical Office, R&D, AstraZeneca, Bangalore 560045, India; (S.S.); (N.K.S.)
Berta Villegas Clinical Operations, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Mississauga, ON L4Y 1M4, Canada;
Tonya Villafana Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA; (K.S.); (V.E.)
Ann R. Falsey Department of Medicine, Infectious Diseases, University of Rochester School of Medicine and Dentistry, Rochester, New York, NY 14642, USA; Infectious Disease, Rochester Regional Health, Rochester, New York, NY 14617, USA
Magdalena E. Sobieszczyk Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian/Columbia University Irving Medical Center, New York, NY 10032, USA; (D.A.T.)

Collapse

D'Arpino MC, Sineli PE, Goroso G, Watanabe W, Saavedra ML, Hebert EM, Martínez MA, Migliavacca J, Gerstenfeld S, Chahla RE, Bellomio A, Albarracín VH. Wastewater monitoring of SARS-CoV-2 gene for COVID-19 epidemiological surveillance in Tucumán, Argentina. J Basic Microbiol 2024;64:e2300773. [PMID: 38712352 DOI: 10.1002/jobm.202300773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 03/12/2024] [Accepted: 04/08/2024] [Indexed: 05/08/2024]

Vanamudhu A, Devi Arumugam R, Nancy A, Selvaraj N, Moiden K, Hissar S, Ranganathan UD, Bethunaickan R, Babu S, Kumar NP. Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population. Viruses 2024;16:1178. [PMID: 39205152 PMCID: PMC11360806 DOI: 10.3390/v16081178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Revised: 07/16/2024] [Accepted: 07/19/2024] [Indexed: 09/04/2024] Open

Ortiz-Ortigosa L, Gálvez-Álvarez P, Viñolo-Gil MJ, Rodriguez-Huguet M, Góngora-Rodríguez J, Martín-Valero R. Effectiveness of pulmonary rehabilitation programmes and/or respiratory muscle training in patients with post-COVID conditions: a systematic review. Respir Res 2024;25:248. [PMID: 38890699 PMCID: PMC11186160 DOI: 10.1186/s12931-024-02857-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 05/24/2024] [Indexed: 06/20/2024] Open

Mielke N, Johnson S, O’Sullivan C, Toseef MU, Bahl A. Updated Bivalent COVID-19 Vaccines Reduce Risk of Hospitalization and Severe Outcomes in Adults: An Observational Cohort Study. J Clin Med Res 2024;16:208-219. [PMID: 38855782 PMCID: PMC11161184 DOI: 10.14740/jocmr5145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2024] [Accepted: 04/24/2024] [Indexed: 06/11/2024] Open

Abstract

Background

This study evaluates the real-world effectiveness of updated bivalent coronavirus disease 2019 (COVID-19) vaccines in adults, as the virus evolves and the need for new vaccinations increases.

Methods

In this observational, retrospective, multi-center, cohort analysis, we examined emergency care encounters with COVID-19 in metro Detroit, Michigan, from January 1, 2022, to March 9, 2023. Patients were categorized by vaccination status: unvaccinated, fully vaccinated, fully vaccinated and boosted (FV&B), or fully vaccinated and bivalent boosted (FV&BB). The primary outcome was to assess the impact of bivalent COVID-19 vaccinations on the risk of composite severe outcomes (intensive care unit (ICU) admission, mechanical ventilation, or death) among patients presenting to a hospital with a primary diagnosis of COVID-19.

Results

A total of 21,439 encounters met inclusion criteria: 9,630 (44.9%) unvaccinated, 9,223 (43.0%) vaccinated, 2,180 (10.2%) FV&B, and 406 (1.9%) FV&BB. The average age was 48.8, with 59.6% female; 61.1% were White, 32.8% Black, and 6.0% other races. Severe disease affected 5.5% overall: 5.0% unvaccinated, 5.7% vaccinated, 7.0% FV&B, and 4.7% FV&BB (P = 0.001). Severe disease rates among admitted patients were 13.3% unvaccinated, 11.9% vaccinated, 12.2% boosted, and 8.1% FV&BB (P = 0.052). The FV&BB group showed a 4.0% (P = 0.0369) lower risk of severe disease compared to FV&B and a 5.1% (P = 0.0203) lower probability of hospitalization.

Conclusions

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate and evolve, updated vaccines are necessary to better combat COVID-19. In a real-world hospital-based population, this investigation demonstrates the incremental benefit of the bivalent booster vaccine in reducing the risk of hospitalization and severe outcomes in those diagnosed with COVID-19 compared to all other forms of vaccination.

Collapse

Hou XY, Danzeng LM, Wu YL, Ma QH, Yu Z, Li MY, Li LS. Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19. World J Stem Cells 2024;16:353-374. [PMID: 38690515 PMCID: PMC11056634 DOI: 10.4252/wjsc.v16.i4.353] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/17/2024] [Accepted: 03/15/2024] [Indexed: 04/25/2024] Open

Shengule S, Alai S, Bhandare S, Patil S, Gautam M, Mangaonkar B, Gupta S, Shaligram U, Gairola S. Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases. Vaccines (Basel) 2024;12:433. [PMID: 38675815 PMCID: PMC11053742 DOI: 10.3390/vaccines12040433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 03/12/2024] [Accepted: 03/23/2024] [Indexed: 04/28/2024] Open

Campos GRF, Almeida NBF, Filgueiras PS, Corsini CA, Gomes SVC, de Miranda DAP, de Assis JV, Silva TBDS, Alves PA, Fernandes GDR, de Oliveira JG, Rahal P, Grenfell RFQ, Nogueira ML. Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol. Front Cell Infect Microbiol 2024;14:1371695. [PMID: 38638823 PMCID: PMC11024236 DOI: 10.3389/fcimb.2024.1371695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 03/14/2024] [Indexed: 04/20/2024] Open

Abstract

Introduction

SARS-CoV-2 vaccines production and distribution enabled the return to normalcy worldwide, but it was not fast enough to avoid the emergence of variants capable of evading immune response induced by prior infections and vaccination. This study evaluated, against Omicron sublineages BA.1, BA.5 and BQ.1.1, the antibody response of a cohort vaccinated with a two doses CoronaVac protocol and followed by two heterologous booster doses.

Methods

To assess vaccination effectiveness, serum samples were collected from 160 individuals, in 3 different time points (9, 12 and 18 months after CoronaVac protocol). For each time point, individuals were divided into 3 subgroups, based on the number of additional doses received (No booster, 1 booster and 2 boosters), and a viral microneutralization assay was performed to evaluate neutralization titers and seroconvertion rate.

Results

The findings presented here show that, despite the first booster, at 9m time point, improved neutralization level against omicron ancestor BA.1 (133.1 to 663.3), this trend was significantly lower for BQ.1.1 and BA.5 (132.4 to 199.1, 63.2 to 100.2, respectively). However, at 18m time point, the administration of a second booster dose considerably improved the antibody neutralization, and this was observed not only against BA.1 (2361.5), but also against subvariants BQ.1.1 (726.1) and BA.5 (659.1). Additionally, our data showed that, after first booster, seroconvertion rate for BA.5 decayed over time (93.3% at 12m to 68.4% at 18m), but after the second booster, seroconvertion was completely recovered (95% at 18m).

Discussion

Our study reinforces the concerns about immunity evasion of the SARS-CoV-2 omicron subvariants, where BA.5 and BQ.1.1 were less neutralized by vaccine induced antibodies than BA.1. On the other hand, the administration of a second booster significantly enhanced antibody neutralization capacity against these subvariants. It is likely that, as new SARS-CoV-2 subvariants continue to emerge, additional immunizations will be needed over time.

Collapse

Affiliation(s)

Guilherme R. F. Campos Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil
Nathalie Bonatti Franco Almeida Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
Priscilla Soares Filgueiras Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
Camila Amormino Corsini Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
Sarah Vieira Contin Gomes Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
Daniel Alvim Pena de Miranda Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
Jéssica Vieira de Assis Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
Thaís Bárbara de Souza Silva Laboratório de Imunologia de Doenças Virais, Instituto Rene Rachou - Fundação Oswaldo Cruz, Belo Horizonte, Brazil
Pedro Augusto Alves Laboratório de Imunologia de Doenças Virais, Instituto Rene Rachou - Fundação Oswaldo Cruz, Belo Horizonte, Brazil
Gabriel da Rocha Fernandes Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
Jaquelline Germano de Oliveira Laboratório de Imunologia Celular e Molecular, instituto Rene Rachou - Fundação Oswaldo Cruz, Belo Horizonte, Brazil
Paula Rahal Laboratório de Estudos Genômicos, Departamento de Biologia, Instituto de Biociências Letras e Ciências Exatas (IBILCE), Universidade Estadual Paulista (Unesp), São José do Rio Preto, Brazil
Rafaella Fortini Queiroz Grenfell Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States
Maurício L. Nogueira Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil Hospital de Base, São José do Rio Preto, Brazil Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States

Collapse

Qian J, Zhang S, Wang F, Li J, Zhang J. What makes SARS-CoV-2 unique? Focusing on the spike protein. Cell Biol Int 2024;48:404-430. [PMID: 38263600 DOI: 10.1002/cbin.12130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 12/25/2023] [Accepted: 01/02/2024] [Indexed: 01/25/2024]

Cahuapaza-Gutierrez NL. Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series. Lupus 2024;33:375-386. [PMID: 38315894 DOI: 10.1177/09612033241232054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2024]

Abstract

OBJECTIVE

Vaccination against SARS-CoV-2 reduced morbidity and mortality rates due to COVID-19 worldwide. However, several adverse effects have been documented and of great interest such as Systemic Lupus Erythematosus (SLE). The aim of the present study was to perform a systematic review of case reports and case series describing the development of SLE following COVID-19 against vaccination.

METHODS

Case report and case series studies were included. Systematic reviews, narratives, letters to the editor, correspondence, etc. were excluded. A selective bibliographic search was performed in the PubMed, Scopus, and EMBASE databases. In addition, the Web of Science platform was consulted. The Joanna Brigs Institute (JBI) tool was used to assess the risk of bias and quality of the studies. The Statistical Package for the Social Sciences (SPSS) 23.0 was used for the formal analysis of the descriptive data.

RESULTS

12 studies met the eligibility criteria and reported a total of 16 patients. The mean age was 42.4 ± 18.69 years. A slight predominance of post-vaccination SLE was observed in females (females (n = 9) and males (n = 7). A higher association was found with Pfizer-BioNTech-162b2 vaccine (75%), followed by Sinopharm (12.5%), Moderna (6.25%). and AstraZeneca (6.25%) vaccines. Most cases were associated with the first dose (56.25%), followed by the second dose (37.5%) and only one case associated with the third dose. The number of days elapsed from vaccine administration to the appearance of the first clinical manifestations was between 1 and 30 days. Mainly there was involvement of the musculoskeletal and cutaneous system. All patients responded well to treatment with good evolution and there was no case of death.

CONCLUSION

Cases of SLE associated with COVID-19 vaccination against are infrequent. However, clinical monitoring is recommended for persons receiving the SARS-CoV-2 vaccine, mainly those receiving the first dose and the Pfizer-BioNTech-162b2 vaccine.

Collapse

Arevalo-Romero JA, Chingaté-López SM, Camacho BA, Alméciga-Díaz CJ, Ramirez-Segura CA. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19. Heliyon 2024;10:e26423. [PMID: 38434363 PMCID: PMC10907543 DOI: 10.1016/j.heliyon.2024.e26423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 02/12/2024] [Accepted: 02/13/2024] [Indexed: 03/05/2024] Open

Abstract

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and MERS in recent decades, underscoring their high potential of infectivity in humans. Insights from previous outbreaks of SARS and MERS have played a significant role in developing effective strategies to mitigate the global impact of SARS-CoV-2. As of January 7, 2024, there have been 774,075,242 confirmed cases of COVID-19 worldwide. To date, 13.59 billion vaccine doses have been administered, and there have been 7,012,986 documented fatalities (https://www.who.int/) Despite significant progress in addressing the COVID-19 pandemic, the rapid evolution of SARS-CoV-2 challenges human defenses, presenting ongoing global challenges. The emergence of new SARS-CoV-2 lineages, shaped by mutation and recombination processes, has led to successive waves of infections. This scenario reveals the need for next-generation vaccines as a crucial requirement for ensuring ongoing protection against SARS-CoV-2. This demand calls for formulations that trigger a robust adaptive immune response without leading the acute inflammation linked with the infection. Key mutations detected in the Spike protein, a critical target for neutralizing antibodies and vaccine design -specifically within the Receptor Binding Domain region of Omicron variant lineages (B.1.1.529), currently dominant worldwide, have intensified concerns due to their association with immunity evasion from prior vaccinations and infections. As the world deals with this evolving threat, the narrative extends to the realm of emerging variants, each displaying new mutations with implications that remain largely misunderstood. Notably, the JN.1 Omicron lineage is gaining global prevalence, and early findings suggest it stands among the immune-evading variants, a characteristic attributed to its mutation L455S. Moreover, the detrimental consequences of the novel emergence of SARS-CoV-2 lineages bear a particularly critical impact on immunocompromised individuals and older adults. Immunocompromised individuals face challenges such as suboptimal responses to COVID-19 vaccines, rendering them more susceptible to severe disease. Similarly, older adults have an increased risk of severe disease and the presence of comorbid conditions, find themselves at a heightened vulnerability to develop COVID-19 disease. Thus, recognizing these intricate factors is crucial for effectively tailoring public health strategies to protect these vulnerable populations. In this context, this review aims to describe, analyze, and discuss the current progress of the next-generation treatments encompassing immunotherapeutic approaches and advanced therapies emerging as complements that will offer solutions to counter the disadvantages of the existing options. Preliminary outcomes show that these strategies target the virus and address the immunomodulatory responses associated with COVID-19. Furthermore, the capacity to promote tissue repair has been demonstrated, which can be particularly noteworthy for immunocompromised individuals who stand as vulnerable actors in the global landscape of coronavirus infections. The emerging next-generation treatments possess broader potential, offering protection against a wide range of variants and enhancing the ability to counter the impact of the constant evolution of the virus. Furthermore, advanced therapies are projected as potential treatment alternatives for managing Chronic Post-COVID-19 syndromeand addressing its associated long-term complications.

Collapse

Wei Z, Wei K, Li Y, Nie L, Zhou Y. Measurement of China's public health level: compilation and research of an index. BMC Public Health 2024;24:686. [PMID: 38439001 PMCID: PMC10913443 DOI: 10.1186/s12889-024-18212-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 02/25/2024] [Indexed: 03/06/2024] Open

Abstract

BACKGROUND

With the development of the economy, public health has become increasingly important. Therefore, it is important to establish a comprehensive and scientific the public health level index (PHL) system to measure public health level as a research priority. The current research has limitations in exploring the PHL system; therefore, the field still lacks a comprehensive indicator system to measure the level of public health. Therefore, this paper aims to develop a multi-level public health index system and utilizes China as a case study to evaluate its public health status. The objective is to offer insights and recommendations for the improvement of public health initiatives in China and other regions.

METHODS

Utilizing data from 2011 to 2020, a comprehensive PHL was developed to encompass three vital indices: the Public Health Service Index (PHS), the Public Health Resource Index (PHR), and the Population Health Level Index (PHL). Subsequently, the PHL, PHS, PHR, and PH were meticulously calculated using a comprehensive evaluation method. Amid the current disparity between public health and economic progress, both the spatial Durbin model and the spatial lag model were finally employed to examine the influence of economic level (EL) on PHL, thus affirming the consistent reliability and accuracy of PHS.

RESULTS

Our findings revealed the following: (i) the PHL, PHS, and PHR indices show increasing trends in China; (ii) both EL and PHL exhibit high-high clustering and low-low clustering states; (iii) the PHL in the area has a positive spatial spillover effect on the surrounding area; (iv) EL will result in the siphoning effect of PHL; and (v) EL can enhance PHL through urbanization, PH, and PHS.

CONCLUSIONS

The PHL system constructed in this paper demonstrates multiple levels, pluralism, spatio-temporal comparability, and robustness. It can reflect not only the input and output of public health initiatives but also the interconnectedness and autonomy within the public health system. Therefore, it can be widely utilized in other areas of public health research.

Collapse

Stróż S, Kosiorek P, Stasiak-Barmuta A. The COVID-19 inflammation and high mortality mechanism trigger. Immunogenetics 2024;76:15-25. [PMID: 38063879 DOI: 10.1007/s00251-023-01326-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 11/29/2023] [Indexed: 02/01/2024]

Li R, Chang Z, Liu H, Wang Y, Li M, Chen Y, Fan L, Wang S, Sun X, Liu S, Cheng A, Ding P, Zhang G. Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2. J Nanobiotechnology 2024;22:44. [PMID: 38291444 PMCID: PMC10825999 DOI: 10.1186/s12951-024-02293-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Accepted: 01/02/2024] [Indexed: 02/01/2024] Open

Affiliation(s)

Ruiqi Li College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China School of Advanced Agricultural Sciences , Peking University, Beijing, 100080, China Longhu Laboratory, Zhengzhou, 450046, China Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China
Zejie Chang College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China College of Animal Medicine, Henan Agricultural University, Zhengzhou, 450046, China
Hongliang Liu School of Life Sciences , Zhengzhou University, Zhengzhou, 450001, China
Yanan Wang Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China College of Animal Medicine, Henan Agricultural University, Zhengzhou, 450046, China
Minghui Li Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China College of Animal Medicine, Henan Agricultural University, Zhengzhou, 450046, China
Yilan Chen Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China
Lu Fan Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China
Siqiao Wang Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China
Xueke Sun Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China College of Animal Medicine, Henan Agricultural University, Zhengzhou, 450046, China
Siyuan Liu Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China College of Animal Medicine, Henan Agricultural University, Zhengzhou, 450046, China
Anchun Cheng College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China
Peiyang Ding School of Life Sciences , Zhengzhou University, Zhengzhou, 450001, China.
Gaiping Zhang College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China. School of Advanced Agricultural Sciences , Peking University, Beijing, 100080, China. Longhu Laboratory, Zhengzhou, 450046, China. Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China. College of Animal Medicine, Henan Agricultural University, Zhengzhou, 450046, China. School of Life Sciences , Zhengzhou University, Zhengzhou, 450001, China.

Collapse

Xu K, Li J, Lu X, Ge X, Wang K, Wang J, Qiao Z, Quan Y, Li C. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice. Vaccines (Basel) 2024;12:60. [PMID: 38250873 PMCID: PMC10819607 DOI: 10.3390/vaccines12010060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 01/04/2024] [Accepted: 01/06/2024] [Indexed: 01/23/2024] Open

Affiliation(s)

Kangwei Xu National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China; (K.X.)
Jing Li Sinovac Life Sciences Co., Ltd., No. 21, Tianfu St., Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing 100050, China
Xu Lu National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China; (K.X.)
Xiaoqin Ge Sinovac Life Sciences Co., Ltd., No. 21, Tianfu St., Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing 100050, China
Kaiqin Wang National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China; (K.X.)
Jiahao Wang Sinovac Life Sciences Co., Ltd., No. 21, Tianfu St., Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing 100050, China
Zhizhong Qiao National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China; (K.X.)
Yaru Quan National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China; (K.X.)
Changgui Li National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China; (K.X.)

Collapse

Pérez P, Albericio G, Astorgano D, Flores S, Sánchez-Corzo C, Sánchez-Cordón PJ, Luczkowiak J, Delgado R, Casasnovas JM, Esteban M, García-Arriaza J. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates. Front Immunol 2023;14:1264323. [PMID: 38155964 PMCID: PMC10754519 DOI: 10.3389/fimmu.2023.1264323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 11/28/2023] [Indexed: 12/30/2023] Open

Affiliation(s)

Patricia Pérez Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain
Guillermo Albericio Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
David Astorgano Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
Sara Flores Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
Cristina Sánchez-Corzo Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
Pedro J. Sánchez-Cordón Pathology Department, Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
Joanna Luczkowiak Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain Instituto de Investigación Hospital Universitario 12 de Octubre (imas12), Madrid, Spain
Rafael Delgado Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain Instituto de Investigación Hospital Universitario 12 de Octubre (imas12), Madrid, Spain Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
José M. Casasnovas Department of Macromolecular Structures, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
Mariano Esteban Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
Juan García-Arriaza Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain

Collapse

Thirión-Romero I, Fernández-Plata R, Pérez-Kawabe M, Meza-Meneses PA, Castro-Fuentes CA, Rivera-Martínez NE, Barrón-Palma EV, Sánchez-Sandoval AL, Cornejo-Juárez P, Sepúlveda-Delgado J, Torres-Erazo DS, Pérez-Padilla JR. SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case-Control Study. Vaccines (Basel) 2023;11:1779. [PMID: 38140183 PMCID: PMC10747324 DOI: 10.3390/vaccines11121779] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 11/12/2023] [Accepted: 11/18/2023] [Indexed: 12/24/2023] Open

Affiliation(s)

Ireri Thirión-Romero Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico; (I.T.-R.); (R.F.-P.)
Rosario Fernández-Plata Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico; (I.T.-R.); (R.F.-P.)
Midori Pérez-Kawabe Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico; (I.T.-R.); (R.F.-P.)
Patricia A. Meza-Meneses Hospital Regional de Alta Especialidad Ixtapaluca (HRAEI), Carretera Federal México-Puebla Km. 34.5, Pueblo de Zoquiapan, Ixtapaluca 56530, Mexico; (P.A.M.-M.); (C.A.C.-F.)
Carlos Alberto Castro-Fuentes Hospital Regional de Alta Especialidad Ixtapaluca (HRAEI), Carretera Federal México-Puebla Km. 34.5, Pueblo de Zoquiapan, Ixtapaluca 56530, Mexico; (P.A.M.-M.); (C.A.C.-F.)
Norma E. Rivera-Martínez Hospital Regional de Alta Especialidad Oaxaca (HRAEO), C. Aldama s/n, Paraje El Tule, San Bartolo Coyotepec 71294, Oaxaca, Mexico;
Eira Valeria Barrón-Palma Hospital General de México (HGM) Eduardo Liceaga, Dr. Balmis 148, Doctores, Cuauhtémoc, Mexico City 06720, Mexico; (E.V.B.-P.)
Ana Laura Sánchez-Sandoval Hospital General de México (HGM) Eduardo Liceaga, Dr. Balmis 148, Doctores, Cuauhtémoc, Mexico City 06720, Mexico; (E.V.B.-P.)
Patricia Cornejo-Juárez Instituto Nacional de Cancerología (INCAN), Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico;
Jesús Sepúlveda-Delgado Hospital Regional de Alta Especialidad Ciudad Salud (HRAECS), Carretera Tapachula Puerto Madero S/N km. 15 + 200, Carretera Federal 225, Col. Los Toros, Tapachula 30830, Chiapas, Mexico;
Darwin Stalin Torres-Erazo Hospital Regional de Alta Especialidad Península de Yucatán (HRAEPY), C. 20 119, Col. Altabrisa, Merida 97130, Yucatán, Mexico;
José Rogelio Pérez-Padilla Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico; (I.T.-R.); (R.F.-P.)

Collapse

Allahverdiyeva A, Ağaçfidan A, Dogan L, Önel M, Uysal HK, Medetalibeyoğlu A, Şenkal N, Alaskarov E, Meşe S. Evaluation of SARS-CoV-2-Positive Patients with Suspected Reinfection. Viruses 2023;15:2222. [PMID: 38005899 PMCID: PMC10675471 DOI: 10.3390/v15112222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 11/02/2023] [Accepted: 11/03/2023] [Indexed: 11/26/2023] Open

Stricker M. Managing hospitalized patients with COVID-19. JAAPA 2023;36:16-20. [PMID: 37751251 DOI: 10.1097/01.jaa.0000977664.94343.68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/27/2023]

Zhang J, Dong P, Liu B, Wang S, Su Y, Xu X, Deng J, Lin Z, Li S, Gu J, Qiu Y, Huang L, Zhou Y. Uncommon Presentation of COVID-19: XBL Variant. Arch Bronconeumol 2023;59:589-590. [PMID: 37414640 PMCID: PMC10266882 DOI: 10.1016/j.arbres.2023.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Revised: 06/10/2023] [Accepted: 06/12/2023] [Indexed: 07/08/2023]

Jin H, Cheng L, Gong Y, Zhu Y, Chong H, Zhang Z, He Y. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. J Virol 2023;97:e0019223. [PMID: 37578234 PMCID: PMC10506475 DOI: 10.1128/jvi.00192-23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 07/02/2023] [Indexed: 08/15/2023] Open

Abstract

Development of highly effective antivirals that are robust to viral evolution is a practical strategy for combating the continuously evolved severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Inspired by viral multistep entry process, we here focus on developing a bispecific SARS-CoV-2 entry inhibitor, which acts on the cell receptor angiotensin converting enzyme 2 (ACE2) and viral S2 fusion protein. First, we identified a panel of diverse spike (S) receptor-binding domains (RBDs) and found that the RBD derived from Guangdong pangolin coronavirus (PCoV-GD) possessed the most potent antiviral potency. Next, we created a bispecific inhibitor termed RBD-IPB01 by genetically linking a peptide fusion inhibitor IPB01 to the C-terminal of PCoV-GD RBD, which exhibited greatly increased antiviral potency via cell membrane ACE2 anchoring. Promisingly, RBD-IPB01 had a uniformly bifunctional inhibition on divergent pseudo- and authentic SARS-CoV-2 variants, including multiple Omicron subvariants. RBD-IPB01 also showed consistently cross-inhibition of other sarbecoviruses, including SARS-CoV, PCoV-GD, and Guangxi pangolin coronavirus (PCoV-GX). RBD-IPB01 displayed low cytotoxicity, high trypsin resistance, and favorable metabolic stability. Combined, our studies have provided a tantalizing insight into the design of broad-spectrum and potent antiviral agent. IMPORTANCE Ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution and spillover potential of a wide variety of sarbecovirus lineages indicate the importance of developing highly effective antivirals with broad capability. By directing host angiotensin converting enzyme 2 receptor and viral S2 fusion protein, we have created a dual-targeted virus entry inhibitor with high antiviral potency and breadth. The inhibitor receptor-binding domain (RBD)-IPB01 with the Guangdong pangolin coronavirus (PCoV-GD) spike RBD and a fusion inhibitor IPB01 displays bifunctional cross-inhibitions on pseudo- and authentic SARS-CoV-2 variants including Omicron, as well as on the sarbecoviruses SARS-CoV, PCoV-GD, and Guangxi pangolin coronavirus. RBD-IPB01 also efficiently inhibits diverse SARS-CoV-2 infection of human Calu-3 cells and blocks viral S-mediated cell-cell fusion with a dual function. Thus, the creation of such a bifunctional inhibitor with pan-sarbecovirus neutralizing capability has not only provided a potential weapon to combat future SARS-CoV-2 variants or yet-to-emerge zoonotic sarbecovirus, but also verified a viable strategy for the designing of antivirals against infection of other enveloped viruses.

Collapse

Samoud S, Bettaieb J, Gdoura M, Kharroubi G, Ben Ghachem F, Zamali I, Ben Hmid A, Salem S, Gereisha AA, Dellagi M, Hogga N, Gharbi A, Baccouche A, Gharbi M, Khemissi C, Akili G, Slama W, Chaieb N, Galai Y, Louzir H, Triki H, Ben Ahmed M. Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial. Vaccines (Basel) 2023;11:1329. [PMID: 37631897 PMCID: PMC10459159 DOI: 10.3390/vaccines11081329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 07/07/2023] [Accepted: 07/07/2023] [Indexed: 08/29/2023] Open

Abstract

(1) Background: This study aimed to compare the immunogenicity of the mix-and-match CoronaVac/BNT162b2 vaccination to the homologous CoronaVac/CoronaVac regimen. (2) Methods: We conducted a simple-blinded randomized superiority trial to measure SARS-CoV-2 neutralization antibodies and anti-spike receptor binding domain (RBD) IgG concentrations in blood samples of participants who had received the first dose of CoronaVac vaccine followed by a dose of BNT162b2 or CoronaVac vaccine. The primary endpoint for immunogenicity was the serum-neutralizing antibody level with a percentage of inhibition at 90% at 21-35 days after the boost. A difference of 25% between groups was considered clinically relevant. (3) Results: Among the 240 eligible participants, the primary endpoint data were available for 100 participants randomly allocated to the mix-and-match group versus 99 participants randomly allocated to the homologous dose group. The mix-and-match regimen elicited significantly higher levels of neutralizing antibodies (median level of 96%, interquartile range (IQR) (95-97) versus median level of 94%, IQR (81-96) and anti-spike IgG antibodies (median level of 13,460, IQR (2557-29,930) versus median level of 1190, IQR (347-4964) compared to the homologous group. Accordingly, the percentage of subjects with a percentage of neutralizing antibodies > 90% was significantly higher in the mix-and-match group (90.0%) versus the homologous (60.6%). Interestingly, no severe events were reported within 30 days after the second dose of vaccination in both groups. (4) Conclusions: Our data showed the superiority of the mix-and-match CoronaVac/BNT162b2 vaccination compared to the CoronaVac/CoronaVac regimen in terms of immunogenicity, thus constituting a proof-of-concept study supporting the use of inactivated vaccines in a mix-and-match strategy while ensuring good immunogenicity and safety.

Collapse

Affiliation(s)

Samar Samoud Department of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (S.S.); (I.Z.); (A.B.H.); (A.A.G.); (Y.G.); (H.L.) Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia
Jihene Bettaieb Department of Medical Epidemiology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (J.B.); (G.K.); (S.S.); (M.D.); (A.G.); (A.B.) Faculty of Medicine of Tunis, University of Tunis, Tunis 1002, Tunisia Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Mariem Gdoura Department of Clinical Virology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (M.G.); (N.H.); (M.G.); (C.K.) Faculty of Pharmacy, University of Monastir, Monastir 5000, Tunisia
Ghassen Kharroubi Department of Medical Epidemiology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (J.B.); (G.K.); (S.S.); (M.D.); (A.G.); (A.B.) Faculty of Medicine of Tunis, University of Tunis, Tunis 1002, Tunisia Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Feriel Ben Ghachem Vaccination Center of Ariana City, Ariana Regional Health Directorate, Ariana 2080, Tunisia; (F.B.G.); (G.A.); (W.S.); (N.C.)
Imen Zamali Department of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (S.S.); (I.Z.); (A.B.H.); (A.A.G.); (Y.G.); (H.L.) Faculty of Medicine of Tunis, University of Tunis, Tunis 1002, Tunisia Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Ahlem Ben Hmid Department of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (S.S.); (I.Z.); (A.B.H.); (A.A.G.); (Y.G.); (H.L.) Faculty of Medicine of Tunis, University of Tunis, Tunis 1002, Tunisia Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Sadok Salem Department of Medical Epidemiology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (J.B.); (G.K.); (S.S.); (M.D.); (A.G.); (A.B.) Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Ahmed Adel Gereisha Department of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (S.S.); (I.Z.); (A.B.H.); (A.A.G.); (Y.G.); (H.L.) Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia
Mongi Dellagi Department of Medical Epidemiology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (J.B.); (G.K.); (S.S.); (M.D.); (A.G.); (A.B.)
Nahed Hogga Department of Clinical Virology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (M.G.); (N.H.); (M.G.); (C.K.)
Adel Gharbi Department of Medical Epidemiology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (J.B.); (G.K.); (S.S.); (M.D.); (A.G.); (A.B.) Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Amor Baccouche Department of Medical Epidemiology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (J.B.); (G.K.); (S.S.); (M.D.); (A.G.); (A.B.) Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Manel Gharbi Department of Clinical Virology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (M.G.); (N.H.); (M.G.); (C.K.) Faculty of Pharmacy, University of Monastir, Monastir 5000, Tunisia
Chadha Khemissi Department of Clinical Virology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (M.G.); (N.H.); (M.G.); (C.K.) Faculty of Pharmacy, University of Monastir, Monastir 5000, Tunisia
Ghada Akili Vaccination Center of Ariana City, Ariana Regional Health Directorate, Ariana 2080, Tunisia; (F.B.G.); (G.A.); (W.S.); (N.C.)
Wissem Slama Vaccination Center of Ariana City, Ariana Regional Health Directorate, Ariana 2080, Tunisia; (F.B.G.); (G.A.); (W.S.); (N.C.)
Nabila Chaieb Vaccination Center of Ariana City, Ariana Regional Health Directorate, Ariana 2080, Tunisia; (F.B.G.); (G.A.); (W.S.); (N.C.)
Yousr Galai Department of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (S.S.); (I.Z.); (A.B.H.); (A.A.G.); (Y.G.); (H.L.) Faculty of Pharmacy, University of Monastir, Monastir 5000, Tunisia
Hechmi Louzir Department of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (S.S.); (I.Z.); (A.B.H.); (A.A.G.); (Y.G.); (H.L.) Faculty of Medicine of Tunis, University of Tunis, Tunis 1002, Tunisia Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;
Henda Triki Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia; Department of Clinical Virology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (M.G.); (N.H.); (M.G.); (C.K.)
Melika Ben Ahmed Department of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, Tunisia; (S.S.); (I.Z.); (A.B.H.); (A.A.G.); (Y.G.); (H.L.) Faculty of Medicine of Tunis, University of Tunis, Tunis 1002, Tunisia Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1068, Tunisia;

Collapse

Mediavilla JR, Lozy T, Lee A, Kim J, Kan VW, Titova E, Amin A, Zody MC, Corvelo A, Oschwald DM, Baldwin A, Fennessey S, Zuckerman JM, Kirn T, Chen L, Zhao Y, Chow KF, Maniatis T, Perlin DS, Kreiswirth BN. Molecular and Clinical Epidemiology of SARS-CoV-2 Infection among Vaccinated and Unvaccinated Individuals in a Large Healthcare Organization from New Jersey. Viruses 2023;15:1699. [PMID: 37632041 PMCID: PMC10457875 DOI: 10.3390/v15081699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 08/01/2023] [Accepted: 08/03/2023] [Indexed: 08/27/2023] Open

Abstract

New Jersey was among the first states impacted by the COVID-19 pandemic, with one of the highest overall death rates in the nation. Nevertheless, relatively few reports have been published focusing specifically on New Jersey. Here we report on molecular, clinical, and epidemiologic observations, from the largest healthcare network in the state, in a cohort of vaccinated and unvaccinated individuals with laboratory-confirmed SARS-CoV-2 infection. We conducted molecular surveillance of SARS-CoV-2-positive nasopharyngeal swabs collected in nine hospitals from December 2020 through June 2022, using both whole genome sequencing (WGS) and a real-time RT-PCR screening assay targeting spike protein mutations found in variants of concern (VOCs) within our region. De-identified clinical data were obtained retrospectively, including demographics, COVID-19 vaccination status, ICU admission, ventilator support, mortality, and medical history. Statistical analyses were performed to identify associations between SARS-CoV-2 variants, vaccination status, clinical outcomes, and medical risk factors. A total of 5007 SARS-CoV-2-positive nasopharyngeal swabs were successfully screened and/or sequenced. Variant screening identified three predominant VOCs, including Alpha (n = 714), Delta (n = 1877), and Omicron (n = 1802). Omicron isolates were further sub-typed as BA.1 (n = 899), BA.2 (n = 853), or BA.4/BA.5 (n = 50); the remaining 614 isolates were classified as "Other". Approximately 31.5% (1577/5007) of the samples were associated with vaccine breakthrough infections, which increased in frequency following the emergence of Delta and Omicron. Severe clinical outcomes included ICU admission (336/5007 = 6.7%), ventilator support (236/5007 = 4.7%), and mortality (430/5007 = 8.6%), with increasing age being the most significant contributor to each (p < 0.001). Unvaccinated individuals accounted for 79.7% (268/336) of ICU admissions, 78.3% (185/236) of ventilator cases, and 74.4% (320/430) of deaths. Highly significant (p < 0.001) increases in mortality were observed in individuals with cardiovascular disease, hypertension, cancer, diabetes, and hyperlipidemia, but not with obesity, thyroid disease, or respiratory disease. Significant differences (p < 0.001) in clinical outcomes were also noted between SARS-CoV-2 variants, including Delta, Omicron BA.1, and Omicron BA.2. Vaccination was associated with significantly improved clinical outcomes in our study, despite an increase in breakthrough infections associated with waning immunity, greater antigenic variability, or both. Underlying comorbidities contributed significantly to mortality in both vaccinated and unvaccinated individuals, with increasing risk based on the total number of comorbidities. Real-time RT-PCR-based screening facilitated timely identification of predominant variants using a minimal number of spike protein mutations, with faster turnaround time and reduced cost compared to WGS. Continued evolution of SARS-CoV-2 variants will likely require ongoing surveillance for new VOCs, with real-time assessment of clinical impact.

Collapse

Affiliation(s)

José R. Mediavilla Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
Tara Lozy Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA Department of Pediatrics, Hackensack University Medical Center, Hackensack, NJ 07601, USA
Annie Lee Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
Justine Kim Hackensack Meridian Health Biorepository, Hackensack, NJ 07601, USA
Veronica W. Kan Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
Elizabeth Titova Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
Ashish Amin Hackensack Meridian Health Biorepository, Hackensack, NJ 07601, USA
Michael C. Zody New York Genome Center, New York, NY 10013, USA (S.F.); (T.M.)
André Corvelo New York Genome Center, New York, NY 10013, USA (S.F.); (T.M.)
Dayna M. Oschwald New York Genome Center, New York, NY 10013, USA (S.F.); (T.M.)
Amy Baldwin New York Genome Center, New York, NY 10013, USA (S.F.); (T.M.)
Samantha Fennessey New York Genome Center, New York, NY 10013, USA (S.F.); (T.M.)
Jerry M. Zuckerman Department of Patient Safety and Quality, Hackensack Meridian Health, Edison, NJ 08837, USA Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
Thomas Kirn Public Health and Environmental Laboratories, New Jersey Department of Health, Ewing, NJ 08628, USA
Liang Chen Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
Yanan Zhao Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
Kar Fai Chow Hackensack Meridian Health Biorepository, Hackensack, NJ 07601, USA Department of Pathology, Hackensack University Medical Center, Hackensack, NJ 07601, USA
Tom Maniatis New York Genome Center, New York, NY 10013, USA (S.F.); (T.M.)
David S. Perlin Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
Barry N. Kreiswirth Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA

Collapse

Tao Z, Xu C, Cheng L, Zhang M, Xu J, Zheng Q, Zhang J, Lu W, Sheng C, Tian J. Tracking trends in COVID-19 vaccines based on 47 different vaccines: A bibliometric review. Hum Vaccin Immunother 2023;19:2242747. [PMID: 37585593 PMCID: PMC10416739 DOI: 10.1080/21645515.2023.2242747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 07/08/2023] [Accepted: 07/27/2023] [Indexed: 08/18/2023] Open

Ma Y, Li J, Cao Y, Li W, Shi R, Jia B, Wang H, Yan L, Suo L, Yang W, Wu J, Feng L. Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China. Hum Vaccin Immunother 2023;19:2235963. [PMID: 37450312 DOI: 10.1080/21645515.2023.2235963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 06/22/2023] [Accepted: 07/10/2023] [Indexed: 07/18/2023] Open

Abstract

The intranasal spray COVID-19 vaccine was made available for the first time in China, it is necessary to understand receivers' satisfaction and experience toward the vaccine to help optimize vaccination service. A self-administered multicenter cross-sectional questionnaire survey was conducted in Beijing, China, in December 2022. The vaccination experience was evaluated through three dimensions: immediate tolerance, smooth progress, and time-saving. Vaccine acceptability was measured by receivers' preference for the intranasal spray over intramuscular injection after vaccination and their recommendation willingness. Stepwise multinomial and binary logistic regression models were applied to investigate factors associated with vaccine acceptability. Among 10,452 participants included in the analysis, 92.6% felt no discomfort during the inoculation, 99.8% thought the vaccination process went well, and 89.4% deemed it a time-saving option. For vaccine acceptability, 5566 (53.3%) participants were willing to recommend the vaccine to others, 534 (5.1%) refused, and 4352 (41.6%) had not decided yet; 6142 (58.8%) participants preferred the intranasal spray, 873 (8.4%) preferred the intramuscular injection, and 3437 (32.9%) had no preferences. The most concerned aspects of the intranasal spray vaccine were vaccine effectiveness and safety. Receivers who perceived higher vaccine effectiveness or safety were more likely to recommend it to others (OR, 95%CI: 4.41, 3.24-6.00; 6.11, 4.52-8.27) or prefer it over intramuscular injection after vaccination (OR, 95%CI: 5.94, 4.62-7.65; 8.50, 6.70-10.78). Receivers showed good acceptability and experience toward the intranasal spray COVID-19 vaccine. Vaccine effectiveness and safety were the most concerned aspects, and corresponding publicity and education efforts may help improve vaccine acceptability.

Collapse

Miteva D, Kitanova M, Batselova H, Lazova S, Chervenkov L, Peshevska-Sekulovska M, Sekulovski M, Gulinac M, Vasilev GV, Tomov L, Velikova T. The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice. Vaccines (Basel) 2023;11:1181. [PMID: 37514997 PMCID: PMC10385722 DOI: 10.3390/vaccines11071181] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 06/22/2023] [Accepted: 06/27/2023] [Indexed: 07/30/2023] Open

Sanecka M, Youssef M, Abdulsalam M, Raza SF, Qadeer A, Ioana J, Aldoresi A, Shah SI, Al Lawati A, Feely J, Tormey WP, O'Neill E, Cormican LJ, Judge EP, McCartney DMA, Faul JL. Hospital Outcomes in Patients Hospitalized for COVID-19 Pneumonia: The Effect of SARS-CoV-2 Vaccination and Vitamin D Status. Nutrients 2023;15:2976. [PMID: 37447302 DOI: 10.3390/nu15132976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 06/24/2023] [Accepted: 06/27/2023] [Indexed: 07/15/2023] Open

Affiliation(s)

Martyna Sanecka School of Biological, Health & Sports Sciences, Technological University Dublin, D07 XT95 Dublin, Ireland
Modar Youssef Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Mohammad Abdulsalam Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Syed F Raza Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Abdul Qadeer Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Julia Ioana Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Alya Aldoresi Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Syed I Shah Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Abdul Al Lawati Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Joseph Feely Department of Biochemistry, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
William P Tormey Department of Biochemistry, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Eoghan O'Neill Department of Microbiology, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Liam J Cormican Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Eoin P Judge Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland
Daniel M A McCartney School of Biological, Health & Sports Sciences, Technological University Dublin, D07 XT95 Dublin, Ireland
John L Faul Department of Respiratory and Sleep Medicine, Connolly Hospital Dublin, D15 X40D Dublin, Ireland Department of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland Department of Medicine, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland

Collapse

Liu J, Lu S, Zheng H. Analysis of Differences in User Groups and Post Sentiment of COVID-19 Vaccine Hesitators in Chinese Social-Media Platforms. Healthcare (Basel) 2023;11:healthcare11091207. [PMID: 37174749 PMCID: PMC10177948 DOI: 10.3390/healthcare11091207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 04/18/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open

Abstract

(1) Background: The COVID-19 epidemic is still global and no specific drug has been developed for COVID-19. Vaccination can both prevent infection and limit the spread of the epidemic. Eliminating hesitation to the COVID-19 vaccine and achieving early herd immunity is a common goal for all countries. However, efforts in this area have not been significant and there is still a long way to go to eliminate vaccine hesitancy. (2) Objective: This study aimed to uncover differences in the characteristics and sentiments of COVID-19 vaccine hesitators on Chinese social-media platforms and to achieve a classification of vaccine-hesitant groups. (3) Methods: COVID-19-vaccine-hesitation posts and user characteristics were collected on the Sina Microblog platform for posting times spanning one year, and posts were identified for hesitation types. Logistic regression was used to conduct user-group analysis. The differences in user characteristics between the various types of COVID-19 vaccine posts were analysed according to four user characteristics: gender, address type, degree of personal-information disclosure, and whether they followed health topics. Sentiment analysis was conducted using sentiment analysis tools to calculate the sentiment scores and sentiment polarity of various COVID-19 vaccine posts, and the K-W test was used to uncover the sentiment differences between various types of COVID-19-vaccine-hesitation posts. (4) Results: There are differences in the types of COVID-19-vaccine-hesitation posts posted by users with different characteristics, and different types of COVID-19-vaccine-hesitation posts differ in terms of sentiment. Differences in user attributes and user behaviors are found across the different COVID-19-vaccine-hesitation types. Ultimately, two COVID-19-vaccine-hesitant user groups were identified: Body-related and Non-bodily-related. Users who posted body-related vaccine-hesitation posts are more often female, disclose more personal information and follow health topics on social-media platforms. Users who posted non-bodily-related posts are more often male, disclose less personal information, and do not follow health topics. The average sentiment score for all COVID-19-vaccine-hesitant-type posts is less than 0.45, with negative-sentiment posts outweighing positive- and neutral-sentiment posts in each type, among which the "Individual rights" type is the most negative. (5) Conclusions: This paper complements the application of user groups in the field of vaccine hesitation, and the results of the analysis of group characteristics and post sentiment can help to provide an in-depth and comprehensive analysis of the concerns and needs of COVID-19 vaccine hesitators. This will help public-health agencies to implement more targeted strategies to eliminate vaccine hesitancy and improve their work related to the COVID-19 vaccine, with far-reaching implications for COVID-19-vaccine promotion and vaccination.

Collapse

Wen C, Liu W, He Z, Liu C. Research on emergency management of global public health emergencies driven by digital technology: A bibliometric analysis. Front Public Health 2023;10:1100401. [PMID: 36711394 PMCID: PMC9875008 DOI: 10.3389/fpubh.2022.1100401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Accepted: 12/23/2022] [Indexed: 01/13/2023] Open

Abstract

Background

The frequent occurrence of major public health emergencies globally poses a threat to people's life, health, and safety, and the convergence development of digital technology is very effective and necessary to cope with the outbreak and transmission control of public epidemics such as COVID-19, which is essential to improve the emergency management capability of global public health emergencies.

Methods

The published literatures in the Web of Science Core Collection database from 2003 to 2022 were utilized to analyze the contribution and collaboration of the authors, institutions, and countries, keyword co-occurrence analysis, and research frontier identification using the CiteSpace, VOSviewer, and COOC software.

Results

The results are shown as follows: (1) Relevant research can be divided into growth and development period and rapid development period, and the total publications show exponential growth, among which the USA, China, and the United Kingdom are the most occupied countries, but the global authorship cooperation is not close; (2) clustering analysis of high-frequency keyword, all kinds of digital technologies are utilized, ranging from artificial intelligence (AI)-driven machine learning (ML) or deep learning (DL), and focused application big data analytics and blockchain technology enabled the internet of things (IoT) to identify, and diagnose major unexpected public diseases are hot spots for future research; (3) Research frontier identification indicates that data analysis in social media is a frontier issue that must continue to be focused on to advance digital and smart governance of public health events.

Conclusion

This bibliometric study provides unique insights into the role of digital technologies in the emergency management of public health. It provides research guidance for smart emergency management of global public health emergencies.

Collapse

Haque MA, Tanbir M, Ahamed B, Hossain MJ, Roy A, Shahriar M, Bhuiyan MA, Islam MR. Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. CLINICAL PATHOLOGY (THOUSAND OAKS, VENTURA COUNTY, CALIF.) 2023;16:2632010X231161222. [PMID: 36938514 PMCID: PMC10014419 DOI: 10.1177/2632010x231161222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 02/15/2023] [Indexed: 03/16/2023]

Ozaka S, Kobayashi T, Mizukami K, Murakami K. COVID-19 vaccination and liver disease. World J Gastroenterol 2022;28:6791-6810. [PMID: 36632314 PMCID: PMC9827578 DOI: 10.3748/wjg.v28.i48.6791] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 11/07/2022] [Accepted: 12/06/2022] [Indexed: 12/26/2022] Open

Peng S, Tian Y, Meng L, Fang R, Chang W, Yang Y, Li S, Shen Q, Ni J, Zhu W. The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review. Front Immunol 2022;13:1103020. [PMID: 36618419 PMCID: PMC9812949 DOI: 10.3389/fimmu.2022.1103020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Accepted: 12/06/2022] [Indexed: 12/24/2022] Open

Abstract

Background

COVID-19 vaccines are required for individuals with myasthenia gravis (MG), as these patients are more likely to experience severe pneumonia, myasthenia crises, and higher mortality rate. However, direct data on the safety of COVID-19 vaccines in patients with MG are lacking, which results in hesitation in vaccination. This scoping was conducted to collect and summarize the existing evidence on this issue.

Methods

PubMed, Cochrane Library, and Web of Science were searched for studies using inclusion and exclusion criteria. Article titles, authors, study designs, demographics of patients, vaccination information, adverse events (AEs), significant findings, and conclusions of included studies were recorded and summarized.

Results

Twenty-nine studies conducted in 16 different countries in 2021 and 2022 were included. Study designs included case report, case series, cohort study, cross-sectional study, survey-based study, chart review, and systemic review. A total of 1347 patients were included. The vaccines used included BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, inactivated vaccines, and recombinant subunit vaccines. Fifteen case studies included 48 patients reported that 23 experienced new-onset, and five patients experienced flare of symptoms. Eleven other types of studies included 1299 patients reported that nine patients experienced new-onset, and 60 participants experienced flare of symptoms. Common AEs included local pain, fatigue, asthenia, cephalalgia, fever, and myalgia. Most patients responded well to treatment without severe sequelae. Evidence gaps include limited strength of study designs, type and dose of vaccines varied, inconsistent window of risk and exacerbation criteria, limited number of participants, and lack of efficacy evaluation.

Conclusion

COVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of population. Large-scale, multicenter, prospective, and rigorous studies are required to verify their safety.

Collapse

Kudlay D, Svistunov A, Satyshev O. COVID-19 Vaccines: An Updated Overview of Different Platforms. Bioengineering (Basel) 2022;9:714. [PMID: 36421115 PMCID: PMC9687223 DOI: 10.3390/bioengineering9110714] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 11/07/2022] [Accepted: 11/14/2022] [Indexed: 07/30/2023] Open

Duan Q, Hu T, Zhu Q, Jin X, Chi F, Chen X. How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development. Front Immunol 2022;13:974433. [PMID: 36172353 PMCID: PMC9510989 DOI: 10.3389/fimmu.2022.974433] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 08/24/2022] [Indexed: 11/13/2022] Open

Shui X, Wang F, Li L, Liang Q. COVID-19 vaccine acceptance among healthcare workers in China: A systematic review and meta-analysis. PLoS One 2022;17:e0273112. [PMID: 35960730 PMCID: PMC9374244 DOI: 10.1371/journal.pone.0273112] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 08/02/2022] [Indexed: 01/09/2023] Open

Abstract

Background

Since the successful development of Coronavirus Disease (COVID-19) vaccine, COVID-19 vaccination has been actively advocated all over the world. As the key population for COVID-19 vaccination, the acceptance of Healthcare Workers (HCWs) is not only related to their risk of contracting COVID-19 infection at work, but also affects the decision of the general population on COVID-19 vaccination. Currently, a series of observational studies have been conducted on the acceptance of COVID-19 vaccines among HCWs in China, but there are presently no all-inclusive reviews. Therefore, this paper reviewed to identify a reliable estimate of acceptance rate of COVID-19 vaccine among HCWs in China.

Methods

We conducted a search on PubMed, EMbase, The Cochrane Library, Web of Science, CNKI (Chinese National Knowledge Infrastructure), Wanfang Database, CBM (Chinese Biomedical Literature Database) and VIP database (Chinese Scientific Journal Database) from January 2020 to June 2022. The quality of included articles was estimated using the Newcastle-Ottawa Quality Assessment tool suitable for cross-sectional studies and STATA 16 was used for analysis, A random-effects model was used to calculate acceptance rate for COVID-19 vaccine, as well as subgroup analysis and sensitivity analysis.

Result

This review included 18 studies involving 45,760 subjects, all of which were of medium or high quality. Meta-analysis results represented that, the pooled estimated acceptance rate of COVID-19 vaccine among HCWs in China was 78% (95%CI: 73–83%), and the pooled acceptance rate in 2021 (82%, 95%CI: 78–86%) was significantly higher than that in 2020 (73%, 95%CI: 65%-81%). Subgroup analysis showed different acceptance rates for COVID-19 vaccine among HCWs with different characteristics.

Conclusion

The result revealed that HCWs in China generally have a high acceptance rate of COVID-19 vaccines, but the acceptance rate varies with different characteristics of the population. Therefore, corresponding training should be carried out for HCWs with different characteristics, and they should play an exemplary and leading role in COVID-19 vaccination, so as to improve the vaccination rate of the whole population and form an immune barrier at an early date.

Collapse